Digitisation | April 19, 2024
Dr. Reddy’s launches integrated care plan to manage irritable bowel syndrome
Around 7% of the Indian population suffers from IBS
Around 7% of the Indian population suffers from IBS
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Submission based on results from pivotal phase III trial showing all primary endpoints met
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
The demand in Africa for COVID-19 vaccines has declined
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Global Phase-3 study initiation expected in the second half of 2024
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Subscribe To Our Newsletter & Stay Updated
